Perspectives on Enquiry & Evidence
Cytel's blog featuring the latest industry insights.
February 2, 2024
When building a disease model or an economic model, the assumption has been that updates to such models should only...
Read article
August 11, 2023
Demonstrating Value in Real Time with Living Models for Systematic Literature Reviews
Systematic literature reviews are essential for proving product value to health authorities, clinicians, and payers,...
Read article
March 24, 2023
Winter Weekend Read Roundup
Last week, we featured our final Winter Weekend Read, the last in a series designed to showcase our complimentary...
Read article
March 3, 2023
Multiple Myeloma Research Benefits from Living Model SLR: A Case Study
The speed of scientific discovery has been outpacing the ability of researchers to accumulate and integrate constantly...
Read article
August 4, 2022
Career Perspectives: Interview with Allison Luccock
In this edition of the Career Perspectives series, I interview Allison Luccock, Director of Business Operations for...
Read article
May 27, 2022
How to Use a Living HTA Approach to Demonstrate Value in Real-Time
When submitting systematic literature reviews to a Health Technology Assessment authority, high volumes of research...
Read article
May 4, 2022
Optimizing Human-Machine Partnership for Up-To-Date Evidence
If you are a pharmaceutical or biotech company seeking to enter the market with a new drug, you need to submit a...
Read article
April 5, 2022
Time Check: Developing New Therapeutics
Hello! I’m delighted to pen my inaugural blog post here as Cytel’s Chief Medical Officer. In this series, we’ll explore...
Read article
December 7, 2021
Anna Forsythe on Aligning Clinical Strategy with Regulatory and Market Objectives
Sponsors bringing a successful new product to market have to overcome two hurdles: submission and reimbursement. For...
Read article
November 17, 2021
Using Tech to align Regulatory and Market Access Evidence strategies
Traditionally, the teams responsible for clinical development and regulatory submissions do not consult the market...
Read article